Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?
Federica Martorana, Gianmarco Motta, Giuliana Pavone, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 173

Showing 1-25 of 173 citing articles:

PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?
Yan Peng, Yuanyuan Wang, Cheng Zhou, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 424
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Feng Ye, Saikat Dewanjee, Yuehua Li, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 228
Targeted therapy for breast cancer: An overview of drug classes and outcomes
Aaron T. Jacobs, Diana Martinez Castaneda-Cruz, Mark M. Rose, et al.
Biochemical Pharmacology (2022) Vol. 204, pp. 115209-115209
Open Access | Times Cited: 81
Targeting Breast Cancer: An Overlook on Current Strategies
Domenico Iacopetta, Jessica Ceramella, Noemi Baldino, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3643-3643
Open Access | Times Cited: 39
Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements
Salima Akter, Md. Ataur Rahman, Mohammad Nazmul Hasan, et al.
Cells (2022) Vol. 11, Iss. 4, pp. 650-650
Open Access | Times Cited: 62
Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast Cancer
Eva Kúdelová, Marek Smolár, Veronika Holubeková, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 14937-14937
Open Access | Times Cited: 62
Current Molecular Combination Therapies Used for the Treatment of Breast Cancer
Yiling Wang, Audrey Minden
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 19, pp. 11046-11046
Open Access | Times Cited: 61
Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways
Zhi Zhu, A. J. Robert McGray, Weijian Jiang, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 54
Mutational signatures are markers of drug sensitivity of cancer cells
Jurica Levatić, Marina Salvadores, Francisco Fuster‐Tormo, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 51
PI3K/AKT Signaling Tips the Balance of Cytoskeletal Forces for Cancer Progression
Shuo Deng, Hin Chong Leong, Arpita Datta, et al.
Cancers (2022) Vol. 14, Iss. 7, pp. 1652-1652
Open Access | Times Cited: 48
Anaplastic Large Cell Lymphoma: Molecular Pathogenesis and Treatment
Xinrui Zhang, Pham Ngoc Chien, Sun‐Young Nam, et al.
Cancers (2022) Vol. 14, Iss. 7, pp. 1650-1650
Open Access | Times Cited: 39
The Importance of the Pyrazole Scaffold in the Design of Protein Kinases Inhibitors as Targeted Anticancer Therapies
George Mihai Niţulescu, Gheorghe Stancov, Oana Cristina Șeremet, et al.
Molecules (2023) Vol. 28, Iss. 14, pp. 5359-5359
Open Access | Times Cited: 30
Proteogenomic insights suggest druggable pathways in endometrial carcinoma
Yongchao Dou, Lizabeth Katsnelson, Marina Gritsenko, et al.
Cancer Cell (2023) Vol. 41, Iss. 9, pp. 1586-1605.e15
Open Access | Times Cited: 22
Targeting the RAS upstream and downstream signaling pathway for Cancer treatment
Md. Arafat Hossain
European Journal of Pharmacology (2024) Vol. 979, pp. 176727-176727
Closed Access | Times Cited: 7
Design, synthesis and biological evaluation of a new series of imidazothiazole-hydrazone hybrids as dual EGFR and Akt inhibitors for NSCLC therapy
Mehlika Dilek Altıntop, İpek Ertorun, Gülşen Akalın Çiftçi, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116698-116698
Closed Access | Times Cited: 7
Dual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-)
Liping Hu, Mengmeng Fan, Shengmin Shi, et al.
European Journal of Medicinal Chemistry (2021) Vol. 227, pp. 113963-113963
Closed Access | Times Cited: 45
Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets
Alexandros Karagiannakos, Maria Adamaki, Antonis Tsintarakis, et al.
Cancers (2022) Vol. 14, Iss. 3, pp. 664-664
Open Access | Times Cited: 33
Resistance to CDK4/6 inhibition: Mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic breast cancer
Marios Papadimitriou, Anastasia Pazaiti, Konstantinos Iliakopoulos, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2022) Vol. 1869, Iss. 12, pp. 119346-119346
Open Access | Times Cited: 31
Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents
Federica Martorana, Leandro Apolinário da Silva, Cristiana Sessa, et al.
Cancers (2022) Vol. 14, Iss. 4, pp. 953-953
Open Access | Times Cited: 27
Advancement in precision diagnosis and therapeutic for triple-negative breast cancer: Harnessing diagnostic potential of CRISPR-cas & engineered CAR T-cells mediated therapeutics
Vinayak Nayak, Sushmita Patra, Kshitij RB Singh, et al.
Environmental Research (2023) Vol. 235, pp. 116573-116573
Closed Access | Times Cited: 16
Ram sperm cryopreservation disrupts metabolism of unsaturated fatty acids
Jones Ofosu, Moses Addo Nartey, Xianhong Mo, et al.
Theriogenology (2023) Vol. 204, pp. 8-17
Closed Access | Times Cited: 15
Inhibitory actions of oxyresveratrol on the PI3K/AKT signaling cascade in cervical cancer cells
Bing Tan, Nitwara Wikan, Shike Lin, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 170, pp. 115982-115982
Open Access | Times Cited: 15
HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review
Linghui Pan, Jinling Li, Qi Xu, et al.
Medicine (2024) Vol. 103, Iss. 24, pp. e38508-e38508
Open Access | Times Cited: 6
The value of protein allostery in rational anticancer drug design: an update
Ruth Nussinov, Hyunbum Jang
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 9, pp. 1071-1085
Open Access | Times Cited: 6
Multiomic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradation
Emily C. Erickson, Inchul You, Grace E. Perry, et al.
Science Signaling (2024) Vol. 17, Iss. 825
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top